Chinese Thoracic Oncology Group
CTONG is the cooperative group of Chinese lung cancer trialists, founded by Yi-Long Wu, whose trials on EGFR-targeted pills before and after surgery changed practice worldwide.
Overview
Founded in 2007 and based at the Guangdong Lung Cancer Institute, CTONG runs investigator-initiated and industry-partnered lung cancer trials across more than 40 Chinese centres: ADJUVANT-CTONG1104 (adjuvant gefitinib), CTONG1103 (neoadjuvant erlotinib), CTONG1509 (bevacizumab plus erlotinib) and contributions to ADAURA and many domestic PD-1 and TKI registration trials. It is the model for Chinese cooperative groups in other cancers.
- Adjuvant and neoadjuvant EGFR-TKI trials
- Multicentre registration trials
- Biomarker studies
Principal investigator of HARMONi-2, the trial where ivonescimab beat pembrolizumab head-to-head, and of the first EGFR-TKI phase 3 in Chinese patients.
A Shanghai lung cancer trialist who has led many Chinese PD-1 and EGFR-TKI phase 3 studies.
Co-led ADAURA and IPASS, the trials that made EGFR-targeted pills standard before and after surgery.
Pages like this
not linked directly; found by shared links- TrialGEMSTONE-302
Shares Caicun Zhou, Non-small-cell lung cancer and the tag china.
- TrialCameL
Shares Caicun Zhou, Non-small-cell lung cancer and the tag china.
- TrialFURLONG
Shares Shun Lu, Non-small-cell lung cancer and the tag china.
- InstitutionJiangsu Cancer Hospital
Shares Non-small-cell lung cancer and the tag china.
- ProductIcotinib
Shares Non-small-cell lung cancer and the tag china.
- TrialALTER 0303
Shares Non-small-cell lung cancer and the tag china.
- TrialORIENT-11
Shares Non-small-cell lung cancer and the tag china.
- ProductGarsorasib
Shares Non-small-cell lung cancer and the tag china.